FDG-PET/PET-CT for Gastrointestinal and Pancreatic Oncology
Customize your policy alerts
Sign up for all blue cross blue shield - kansas policy alerts
Know when blue cross blue shield - kansas releases new policies or updates existing guidance.
Monitor payer policy activity
This policy defines when fluorine-18 FDG PET or PET/CT is considered medically necessary, investigational, or not medically necessary for diagnosis, staging, restaging, and surveillance of colorectal, esophageal, gastric, and pancreatic cancers for Blue Cross and Blue Shield of Kansas members.
No material clinical or coverage changes in this revision.
Coverage Criteria — FDG-PET / PET-CT for GI and Pancreatic Cancers
Initial/Restaging and Rising CEA
Colorectal cancer — FDG-PET or FDG-PET/CT may be considered medically necessary when ALL of the following are met
From policy section A.1
Colorectal - Experimental/Investigational Uses
Colorectal cancer — Experimental / investigational (Not covered)
From policy section A.2
Esophageal - Staging and Response Assessment
Esophageal cancer — FDG-PET or FDG-PET/CT may be considered medically necessary when ALL of the following are met
From policy section B.1
Esophageal - Experimental/Investigational Uses
Esophageal cancer — Experimental / investigational (Not covered)
From policy section B.2
Gastric - Initial Staging and Recurrent Disease
Gastric cancer — FDG-PET or FDG-PET/CT may be considered medically necessary when ALL of the following are met
From policy section C.1
Pancreatic - Initial Diagnosis/Staging when other tests inconclusive
Pancreatic cancer — FDG-PET or FDG-PET/CT may be considered medically necessary when ALL of the following are met
From policy section D.1
Pancreatic - Experimental/Investigational Uses
Pancreatic cancer — Experimental / investigational (Not covered)
From policy section D.2
Colorectal cancer (CRC) coverage rationale
Findings from systematic reviews, meta-analyses, and a randomized trial inform coverage stance for colorectal cancer:
See pooled estimates in chunks 25, 28, 30.
See chunks 31 and 35.
Guideline-based use constraints and recommended uses
Guideline-based constraints and recommended uses:
Based on ACR and NCCN guidance (chunks 32-34).
Based on NCCN and ACR statements (chunks 32-34).
Esophageal cancer
Esophageal cancer evidence summary:
Chunk 36.
Chunk 37.
Esophageal Cancer - Supported Uses
Covered when ALL of the following are met for esophageal cancer:
Guidelines (ACR, NCCN) consider PET/CT appropriate for pretreatment staging and post-treatment imaging; PET alone is less favored for initial tumor detection.
Gastric Cancer - Supported Uses
Covered when ALL of the following are met for gastric cancer:
NCCN allows FDG-PET/CT as part of initial workup for locally advanced or metastatic disease and when clinically indicated; CT preferred for routine surveillance.
Pancreatic Cancer - Conditional Uses
Covered when ALL of the following are met for pancreatic cancer:
NCCN and ACR: consider PET/CT after formal pancreatic CT protocol in high-risk patients; evidence shows PET/CT can improve detection of distant metastases compared with CT alone (Ghaneh et al).
Table 3: National FDG PET Coverage by tumor type and treatment strategy
National FDG PET Coverage (Table 3) — coverage stance by tumor type and treatment strategy
Table 3 summary (chunk 57)
Table 3 summary (chunk 57)
Table 3 summary (chunk 58)
Table 3 summary (chunk 58)
Table 3 summary (chunks 57-59)
Colorectal cancer: FDG‑PET or FDG‑PET/CT may be considered medically necessary when both of the following criteria are met: (1) staging or restaging to detect and assess resectability of hepatic or extrahepatic metastases; AND (2) evaluation of a rising and persistently elevated carcinoembryonic antigen (CEA) level when standard imaging (including CT) is negative. This policy position reflects pooled diagnostic evidence showing high sensitivity but variable and at times low specificity for primary, nodal, metastatic, and recurrent disease, and randomized trial data that adding scheduled PET/CT to routine surveillance did not improve outcomes (RCT N=239). Clinicians should follow guideline recommendations (eg, NCCN) that PET/CT not supplant contrast‑enhanced diagnostic CT or MRI and to reserve PET/CT for equivocal anatomic findings, contraindication to IV contrast, selected patients considered for liver‑directed therapies, or when rising CEA is unexplained by other imaging.
Colorectal — Experimental/Investigational (Not covered): FDG‑PET or FDG‑PET/CT is considered experimental/investigational and not covered for (a) assessing scarring versus local bowel recurrence after prior resection and (b) contribution to radiotherapy treatment planning. The overall evidence does not demonstrate a benefit of routine PET or PET/CT over contrast‑enhanced CT for diagnosis, staging, restaging, or surveillance of colorectal cancer, and major guidelines (NCCN) strongly discourage routine PET/CT for staging, baseline imaging, or routine follow‑up except in the limited, guideline‑specified circumstances noted above.
Esophageal cancer — Supported uses: FDG‑PET or FDG‑PET/CT may be considered medically necessary for staging of esophageal cancer and for determining response to preoperative induction (neoadjuvant) therapy. Evidence from meta‑analyses demonstrates high sensitivity and supports use of PET/CT for diagnosis, staging, restaging, and response assessment in selected patients; relevant guidelines (ACR, NCCN) endorse PET/CT (not PET alone) for pretreatment staging and for assessment of treatment response in appropriate clinical contexts.
Esophageal — Experimental/Investigational (Not covered): FDG‑PET or FDG‑PET/CT is considered experimental/investigational and not covered for indications outside those listed as medically necessary, including the use of PET (alone) to detect primary esophageal cancer. PET alone is generally not considered useful to detect primary esophageal tumors or to distinguish malignant from benign esophageal conditions.
Gastric cancer — Supported uses: FDG‑PET or FDG‑PET/CT may be considered medically necessary for initial diagnosis and staging of gastric cancer and for evaluation of suspected recurrent gastric cancer after resection when other imaging modalities are inconclusive. Meta‑analyses report pooled sensitivity estimates generally in the high 70s to mid‑80s and specificity in the high 70s to high 80s; guidelines (eg, NCCN) permit FDG‑PET/CT as part of the initial workup for locally advanced or metastatic gastric disease or when clinically indicated. Routine surveillance with PET or PET/CT is not supported by the evidence.
Pancreatic cancer — Conditional uses: FDG‑PET or FDG‑PET/CT may be considered medically necessary for initial diagnosis and staging when high‑quality contrast‑enhanced CT and biopsy are inconclusive or when PET/CT is expected to detect additional distant metastases that would alter management. Systematic reviews and a large observational study show that PET/CT can improve detection of distant metastases compared with CT alone in selected patients; however, PET/CT is not supported as a routine substitute for diagnostic CT, nor is it supported for routine staging, restaging, or surveillance.
Table 3 — National FDG PET Coverage by tumor type and treatment strategy: The national FDG PET coverage summary indicates that FDG‑PET is generally listed as Cover for both initial and subsequent treatment strategies for colorectal, esophageal, pancreatic, and most other solid tumors, with specific exceptions (for example, prostate cancer initial treatment strategy is listed as Non‑cover). These table entries reflect a broad national coverage framework but do not replace the clinical‑indication‑specific policy criteria in this document; coverage remains contingent on meeting the policy's stated medical‑necessity criteria and the member's contract.
Not medically necessary / clinical impact requirement: When the PET or PET/CT result will not influence treatment decisions, the service is considered not medically necessary and may be denied. This policy applies to both PET alone and PET with CT; codes listed in the coding section are medically necessary only if the procedure is performed in accordance with the policy criteria. For colorectal cancer specifically, evidence and guideline summaries do not support routine use of FDG‑PET or PET/CT for diagnosis, staging, restaging, or surveillance.
Routine use not supported for colorectal disease: Use of FDG‑PET and FDG‑PET/CT for routine diagnosis, initial staging, restaging, or surveillance of colorectal cancer is not supported by the evidence. A randomized trial that added 6‑monthly FDG‑PET/CT to usual surveillance in patients in remission found no statistically significant improvement in outcomes compared with usual surveillance alone. Major guidelines (NCCN) strongly discourage routine PET/CT for initial staging or routine follow‑up and recommend PET/CT be reserved for the limited situations described above.
Covered Indications and Acceptable Uses
Colorectal cancer
Colorectal cancer — single top-level coverage node
Coverage criterion (Chunk 9)
Esophageal cancer
Esophageal cancer — single top-level coverage node
Coverage criterion (Chunk 10)
Gastric cancer
Gastric cancer — single top-level coverage node
Coverage criterion (Chunk 11)
Pancreatic cancer
Pancreatic cancer — single top-level coverage node
Coverage criterion (Chunk 12)
Acceptable selective uses of PET/CT in GI cancers (not routine)
Acceptable selective uses of PET/CT in GI cancers (not routine) — top-level nodes:
NCCN/ACR guidance (Chunks 33-34).
NCCN/ACR guidance and clinical context (Chunks 26, 33-34).
Based on evidence and guidelines (Chunks 26, 30, 33).
Staging and response assessment
Staging and response assessment — coverage node
ACR/NCCN recommendations (Chunks 39, 40, 51).
Pancreatic staging when CT inconclusive
Pancreatic staging when CT inconclusive — coverage node
ACR and NCCN guidance (Chunks 50-52).
FDG-PET/PET-CT oncologic indications summarized
FDG-PET/PET-CT oncologic indications summarized in national coverage table:
Table 3 summary (Chunks 56-59).
Provider Actions, Prior Authorization, and Documentation
Prior authorization applies to PET and PET/CT; evaluate by indication and timing
Prior authorization processes should treat PET and PET/CT equivalently: PET scans and PET plus CT scans are evaluated for medical necessity based on the specific clinical indication and timing (for example, surveillance is defined as imaging ≥6 months after treatment, or ≥12 months for lymphoma).
- Policy statements apply to both PET alone and PET+CT.
- Medical necessity determinations depend on indication and timing (surveillance threshold: ≥6 months; ≥12 months for lymphoma).
Prior authorization recommended for PET/CT requests outside guideline-supported indications
Obtain prior authorization when requesting PET/CT for staging, restaging, or surveillance outside guideline-supported indications (eg, routine baseline imaging or surveillance). Requests for PET/CT to evaluate equivocal anatomic findings, in patients with contraindication to IV contrast, or for selected preoperative/ liver-directed therapy cases are the guideline-supported exceptions.
- NCCN: routine PET/CT for staging, baseline imaging, or routine follow-up is strongly discouraged.
- Use PET/CT only for equivocal contrast-enhanced CT/MR findings or when IV contrast is contraindicated, or in selected cases (eg, potentially resectable M1 disease or image-guided liver-directed therapy).
Require prior pancreatic CT protocol before PET/CT for staging
For pancreatic cancer staging, prior high-quality contrast-enhanced CT performed with a formal pancreatic CT protocol is expected before considering PET/CT; PET/CT may be considered only after that pancreatic CT protocol in high-risk patients to detect extrapancreatic metastasis.
- NCCN: PET/CT may be considered after formal pancreatic CT protocol in high-risk patients and is not a substitute for high-quality contrast-enhanced CT.
- Documentation of prior pancreatic CT protocol should be available when seeking PET/CT for pancreatic staging.
Codes provided for informational/prior-authorization use; coverage depends on Policy
The policy lists procedure and radiopharmaceutical codes for informational and prior-authorization relevance; inclusion of codes does not by itself imply coverage and codes are medically necessary only if procedure is performed according to the Policy section.
(No additional provider action in source)
The source does not include additional provider-action requirements under this placeholder.
Require prior contrast-enhanced CT/MRI before PET/CT unless contraindicated
Require prior diagnostic anatomic imaging (contrast-enhanced CT or MRI) be available and reviewed before approving PET/CT except when IV contrast is contraindicated or when PET/CT is otherwise specifically indicated.
- PET/CT should not routinely replace contrast-enhanced diagnostic CT or MRI when those studies are available and diagnostic.
- Exceptions include equivocal findings on anatomic imaging or strong contraindication to IV contrast.
Perform pancreatic CT protocol first; PET/CT only afterward for extrapancreatic metastasis
When evaluating for extrapancreatic metastasis in suspected pancreatic cancer, require completion of a formal contrast-enhanced pancreatic CT protocol first; consider PET/CT only if that CT protocol is complete and CT is inconclusive or additional metastatic evaluation is needed.
- PET/CT is not a substitute for high-quality contrast-enhanced CT.
- NCCN recommends PET/CT consideration after formal pancreatic CT protocol in high-risk patients.
(No additional provider action in source)
The source does not identify additional provider-action text for this placeholder beyond existing requirements.
Confirm surveillance timing for prior authorization (≥6 months; ≥12 months for lymphoma)
For surveillance requests, verify timing relative to treatment: imaging is considered surveillance when completed ≥6 months after completion of treatment (and ≥12 months for lymphoma); prior authorization should reflect these timing thresholds.
- Surveillance definition: ≥6 months post-treatment (≥12 months for lymphoma).
- Use timing to determine whether request is for surveillance versus restaging.
Document limited PET/CT use: equivocal CT/MRI, contrast contraindication, or other exceptions
Include documentation that PET/CT is limited to situations of equivocal anatomic imaging, IV contrast contraindication, selection for liver-directed therapies, or other guideline-supported exceptions when seeking prior authorization.
- Documentation should state why contrast-enhanced CT/MRI is non-diagnostic or why IV contrast cannot be used.
- Indicate intended clinical management changes (eg, selection for liver-directed therapy) to support necessity.
Document prior CT and clinical rationale when PET/CT is adjunct or CT is inconclusive
When PET/CT is requested as an adjunct after CT or because CT is inconclusive, submit prior CT images and a clinical rationale explaining how PET/CT results are expected to change management.
- Provide prior high-quality CT imaging used in the diagnostic workup (eg, multidetector CT).
- Explain expected impact of PET/CT on staging or treatment decisions (management-impact rationale).
Coding note: codes medically necessary only if procedure meets Policy criteria
Codes listed in the Coding section are medically necessary only if the procedure is performed in accordance with the Policy section; inclusion of codes does not guarantee member coverage or provider reimbursement.
- Refer to the Policy section and member contract benefits at time of service to determine coverage.
- Presence of a code in the list is informational and not a standalone coverage determination.
Deny if PET results will not influence treatment decisions
Requests may be denied if PET/PET-CT results are unlikely to influence treatment decisions; the policy states services are not medically necessary when results will not affect management.
- Prior authorization should include a statement of how PET results will influence care.
- If no plausible management change is documented, coverage may be denied as not medically necessary.
NCCN discouragement of routine PET/CT in colon cancer may trigger denial
Routine or non-guideline PET/CT use in colon cancer may be denied consistent with NCCN guidance, which strongly discourages routine PET/CT for staging, baseline imaging, or routine follow-up.
- NCCN: PET/CT not routinely indicated for initial workup of nonmetastatic disease; discouraged for routine follow-up.
- Prior authorization should reference NCCN guidance when evaluating colon cancer PET/CT requests.
Surveillance PET/CT for esophageal, gastric, or pancreatic cancer is unsupported and may be denied
Requests for PET or PET/CT for routine surveillance in esophageal, gastric, or pancreatic cancer are unsupported by the evidence and may be denied.
- Evidence sections state that surveillance use is not supported for esophageal, gastric, or pancreatic cancers.
- Prior authorization should flag surveillance requests for these tumor types for potential denial.
Coverage contingent on meeting Policy criteria despite listed codes
Inclusion or exclusion of procedure or diagnosis codes in the Coding section does not by itself determine member coverage or provider reimbursement; coverage is contingent on the Policy criteria and the member's contract.
- Verify member contract benefits at time of service.
- Confirm the procedure meets Policy clinical criteria to establish medical necessity.
Coding and Billing Guidance
| 18F-FDG-PET | Fluorine-18 fluorodeoxyglucose positron emission tomography (as described in policy) |
| 18F-FDG-PET/CT | Fluorine-18 fluorodeoxyglucose PET with computed tomography fusion |
| POLICY | All policy statements apply to both PET scans and PET plus CT scans (PET with or without PET/CT fusion). |
| 78608 | Brain imaging, positron emission tomography (PET); metabolic evaluation |
| 78609 | Brain imaging, positron emission tomography (PET); perfusion evaluation |
| 78811 | Positron emission tomography (PET) imaging; limited area (e.g. Chest, head/neck) |
| 78812 | Positron emission tomography (PET) imaging; skull base to mid-thigh |
| 78813 | Positron emission tomography (PET) imaging; whole body |
| 78814 | Tumor imaging, positron emission tomography (PET) with concurrently acquired CT; limited area (e.g. chest, head/neck) |
| 78815 | Tumor imaging, positron emission tomography (PET) with concurrently acquired CT; skull base to mid-thigh |
| 78816 | Tumor imaging, positron emission tomography (PET) with concurrently acquired CT; whole body |
| A9552 | Fluorodeoxyglucose F-18 FDG, diagnostic, per study dose, up to 45 millicuries |
| A9597 | Positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified |
Informational list of PET procedure and radiopharmaceutical codes
Procedure and radiopharmaceutical codes are listed for informational and prior-authorization relevance; see Coding section for the CPT/HCPCS codes included in the policy.
Contrast and Anatomic Imaging Rules
Policy applies to PET alone and PET plus CT
Policy statements explicitly apply to PET scans and PET plus CT scans (PET with or without PET/CT fusion); treat both modalities under the same coverage rules.
- All policy statements apply to both PET and PET+CT.
- When submitting prior authorization, indicate whether PET alone or PET/CT is requested but expect equivalent evaluation.
Do not substitute PET/CT for diagnostic contrast-enhanced CT/MRI when those studies are available
When a diagnostic contrast-enhanced CT or MRI is available and is diagnostic, PET/CT should not routinely replace that anatomic imaging; PET/CT should be reserved for equivocal anatomic findings or when IV contrast cannot be used.
- PET/CT does not supplant contrast-enhanced diagnostic CT/MR and should be used to evaluate equivocal findings or in contrast-contraindicated patients.
- Prior authorization should document why contrast-enhanced anatomic imaging is inadequate if PET/CT is requested instead.
PET/CT is not a substitute for high-quality pancreatic contrast CT; use only after pancreatic CT protocol
For pancreatic imaging, PET/CT is not a substitute for high-quality, contrast-enhanced CT; PET/CT may be considered only after completion of a formal pancreatic CT protocol or when CT contrast cannot be used (eg, renal insufficiency or contrast allergy).
- NCCN: PET/CT may be considered after formal pancreatic CT protocol in high-risk patients to detect extrapancreatic metastasis.
- Document contraindications to CT contrast if relying on PET/CT due to inability to perform contrast-enhanced CT.
Not Medically Necessary / Not Covered Uses
Examples of not-covered scenarios provided in the policy include: using PET to detect a primary esophageal cancer (PET alone is not appropriate for primary detection), employing PET to distinguish scarring versus local recurrence in colorectal cancer after resection, and other pancreatic applications that are not specified as medically necessary. These examples are identified as experimental/investigational and therefore not covered.
Requests for routine PET/CT for staging, baseline imaging, routine surveillance, or to assess chemotherapy response in colorectal or rectal cancer are not supported by current guidelines (NCCN/ACR) and the evidence. The policy and guideline statements strongly discourage routine PET/CT in these scenarios except in selected circumstances (eg, equivocal anatomic imaging or suspected resectable M1 disease).
The policy emphasizes that PET alone is inadequate for detecting primary esophageal tumors and that PET or PET/CT is not supported for routine surveillance across esophageal, gastric, and pancreatic cancers. These conclusions are drawn from systematic reviews and guideline recommendations summarized in the document.
Additional not-covered language in the policy reiterates that specific applications outside the listed medically necessary indications—such as other diagnostic uses not enumerated for colorectal, esophageal, gastric, or pancreatic cancers—are considered experimental or investigational and not covered.
Definitions and Test Concepts
Background and Evidence Overview
Positron emission tomography (PET) is a nuclear imaging modality that uses positron-emitting radiotracers—most commonly 18F-FDG—to image tissue metabolic activity. Tracer selection depends on tumor type and clinical question. The policy notes PET and PET/CT can detect metabolically active disease not seen on conventional imaging and that evidence reviews evaluate whether PET is technically reliable, clinically valid, and clinically useful for specific oncologic purposes. Literature surveillance for this review was updated through September 17, 2025.
References, Supplemental Tables, and Evidence Appendix
Table 3 in the policy compiles national FDG PET coverage by tumor type and treatment strategy and is supported by the supplemental references. The table lists coverage status for multiple cancers (for example, colorectal, esophagus, and pancreas are shown as "Cover" for initial and subsequent strategies) and the supplemental material and references provide the source list used to construct the national coverage summary.
Administrative notes in the policy indicate this gastrointestinal and pancreatic oncologic guidance was split into a separate document; coding and policy language are referenced for prior authorization and claims processing. The coding section clarifies that codes included are informational and that prior authorization requirements depend on the policy criteria and the member's contract.
The evidence surveillance and literature update section reports the review was informed by systematic reviews, meta-analyses, and primary studies and that the most recent literature update was performed through September 17, 2025. This date should be used as the reference point for the currency of the evidence cited in the policy.
The policy includes a supplemental references section listing systematic reviews, meta-analyses, guidelines, and trials (see referenced items such as Mahmud et al, Yu et al, Sobhani et al, and ACR/NCCN guidance). These references are provided to substantiate diagnostic accuracy estimates, guideline-based recommendations, and the randomized trial and observational studies referenced throughout the policy.
Revision History and Document Dates
Last formal policy review completed; document status marked CURRENT and review dates set to 2026-01-13.
Most recent literature surveillance / evidence update performed through September 17, 2025.
Policy content for Oncologic Applications — Gastrointestinal and Pancreatic was posted (referenced posting date).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.